Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
120.85
-0.02 (-0.02%)
At close: Apr 6, 2026, 4:00 PM EDT
120.50
-0.35 (-0.29%)
After-hours: Apr 6, 2026, 5:49 PM EDT
Merck & Co. Employees
Merck & Co. had 75,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$866,813
Profits / Employee
$243,387
Market Cap
298.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
MRK News
- 3 days ago - Swiss industry body says US tariffs on pharmaceuticals will harm patients - Reuters
- 4 days ago - Trump Administration Unveils Up to 100% Tariff on Branded Drugs - WSJ
- 4 days ago - Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices - The Guardian
- 4 days ago - Drugmakers face 100% tariff unless they cut prices or produce drugs in US - Reuters
- 4 days ago - Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
- 4 days ago - Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - Business Wire
- 4 days ago - European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens - Business Wire
- 5 days ago - Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 - Business Wire